LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance
Sijia He,Jiyoon Ryu,Juanhong Liu,Hairong Luo,Ying Lv,Paul R. Langlais,Jie Wen,Feng Dong,Zhe Sun,Wenjuan Xia,Jane L. Lynch,Ravindranath Duggirala,Bruce J. Nicholson,Mengwei Zang,Yuguang Shi,Fang Zhang,Feng Liu,Juli Bai,Lily Q. Dong
DOI: https://doi.org/10.1172/jci148545
IF: 19.456
2021-12-15
Journal of Clinical Investigation
Abstract:Dysregulation in adipokine biosynthesis and function contributes to obesity-induced metabolic diseases. However, the identities and functions of many of the obesity-induced secretory molecules remain unknown. Here, we report the identification of leucine-rich alpha-2-glycoprotein 1 (LRG1) as an obesity-associated adipokine that exacerbates high fat diet-induced hepatosteatosis and insulin resistance. Serum levels of LRG1 were markedly elevated in obese humans and mice compared with their respective controls. LRG1 deficiency in mice greatly alleviated diet-induced hepatosteatosis, obesity, and insulin resistance. Mechanistically, LRG1 bound with high selectivity to the liver and promoted hepatosteatosis by increasing de novo lipogenesis and suppressing fatty acid β-oxidation. LRG1 also inhibited hepatic insulin signaling by downregulating insulin receptor substrates 1 and 2. Our study identified LRG1 as a key molecule that mediates the crosstalk between adipocytes and hepatocytes in diet-induced hepatosteatosis and insulin resistance. Suppressing LRG1 expression and function may be a promising strategy for the treatment of obesity-related metabolic diseases.
medicine, research & experimental